Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.

Gianotti N, Mondino V, Rossi MC, Chiesa E, Mezzaroma I, Ladisa N, Guaraldi G, Torti C, Tarquini P, Castelli P, Di Carlo A, Boeri E, Keulen W, Kenna PM, Lazzarin A; Mutations and Salvage (MuSa) Study Group.

Clin Infect Dis. 2006 May 15;42(10):1470-80. Epub 2006 Apr 13.

PMID:
16619162
2.

A Grid-based HIV expert system.

Sloot PM, Boukhanovsky AV, Keulen W, Tirado-Ramos A, Boucher CA.

J Clin Monit Comput. 2005 Oct;19(4-5):263-78.

PMID:
16328942
3.

Tenofovir resistance and resensitization.

Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, Lengauer T, Selbig J, Vandamme AM, Korn K, Schmidt B.

Antimicrob Agents Chemother. 2003 Nov;47(11):3478-84.

4.

Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.

Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C; GenPherex Study Group of the MaSTeR Cohort.

J Infect Dis. 2003 Jul 15;188(2):194-201. Epub 2003 Jul 1.

PMID:
12854073
5.

Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.

Maxeiner HG, Keulen W, Schuurman R, Bijen M, de Graaf L, van Wijk A, Back N, Kline MW, Boucher CA, Nijhuis M.

J Infect Dis. 2002 Apr 15;185(8):1070-6. Epub 2002 Apr 1.

PMID:
11930317
6.

Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.

Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B.

Virology. 2001 May 10;283(2):294-305.

7.

Estimating relative fitness in viral competition experiments.

Marée AF, Keulen W, Boucher CA, De Boer RJ.

J Virol. 2000 Dec;74(23):11067-72.

8.

Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential.

Keulen W, van Wijk A, Schuurman R, Berkhout B, Boucher CA.

AIDS. 1999 Jul 30;13(11):1343-9.

PMID:
10449287
9.

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.

Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange J, Danner S, Keulen W, de Groot T, Boucher CA.

J Infect Dis. 1997 Aug;176(2):398-405.

PMID:
9237704
11.

Reverse transcriptase fidelity and HIV-1 variation.

Keulen W, Nijhuis M, Schuurman R, Berkhout B, Boucher C.

Science. 1997 Jan 10;275(5297):229; author reply 230-1. No abstract available.

PMID:
8999550
12.

Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.

Boucher CA, Keulen W, van Bommel T, Nijhuis M, de Jong D, de Jong MD, Schipper P, Back NK.

Antimicrob Agents Chemother. 1996 Oct;40(10):2404-9.

13.

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B.

EMBO J. 1996 Aug 1;15(15):4040-9.

14.

Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins.

Keulen W, Boucher C, Berkhout B.

Antiviral Res. 1996 Jun;31(1-2):45-57.

PMID:
8793008
15.

An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.

Back NK, Smit L, De Jong JJ, Keulen W, Schutten M, Goudsmit J, Tersmette M.

Virology. 1994 Mar;199(2):431-8.

PMID:
8122371
17.

Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype.

Kuiken CL, de Jong JJ, Baan E, Keulen W, Tersmette M, Goudsmit J.

J Virol. 1992 Sep;66(9):5704. No abstract available.

18.
19.

Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes.

de Ronde A, Klaver B, Keulen W, Smit L, Goudsmit J.

Virology. 1992 May;188(1):391-5.

PMID:
1566581
20.

Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.

de Jong JJ, Goudsmit J, Keulen W, Klaver B, Krone W, Tersmette M, de Ronde A.

J Virol. 1992 Feb;66(2):757-65.

21.

Modified protocol for DNA sequence analysis using Sequenase 2.0.

Schuurman R, Keulen W.

Biotechniques. 1991 Feb;10(2):185. No abstract available.

PMID:
1647804
22.

Characterization of the African HIV-1 isolate CBL-4 (RUT) by partial sequence analysis and virus neutralization with peptide antibody and antisense phosphate-methylated DNA.

Goudsmit J, Geelen J, Keulen W, Notermans D, Kuiken C, Ramautarsing C, Smit L, Koole L, van Genderen M, Buck H, et al.

AIDS. 1990 Jun;4(6):559-64. Erratum in: AIDS 1990 Dec;4(12):A72. AIDS 1990 Jul;4(7):following A44.

PMID:
2201319
23.

Use of recombinant antigens expressed in Escherichia coli K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of Mycobacterium bovis BCG.

Thole JE, van Schooten WC, Keulen WJ, Hermans PW, Janson AA, de Vries RR, Kolk AH, van Embden JD.

Infect Immun. 1988 Jun;56(6):1633-40.

24.

Characterization, sequence determination, and immunogenicity of a 64-kilodalton protein of Mycobacterium bovis BCG expressed in escherichia coli K-12.

Thole JE, Keulen WJ, De Bruyn J, Kolk AH, Groothuis DG, Berwald LG, Tiesjema RH, van Embden JD.

Infect Immun. 1987 Jun;55(6):1466-75. Erratum in: Infect Immun 1987 Aug;55(8):1949.

Supplemental Content

Loading ...
Support Center